Affordable Access

A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.

Authors
  • Colombo, Giorgio L
  • Di Matteo, Sergio
  • Peris, Ketty
  • Fargnoli, Maria Concetta
  • Esposito, Maria
  • Mazzotta, Annamaria
  • Chimenti, Sergio
Type
Published Article
Journal
ClinicoEconomics and outcomes research : CEOR
Publication Date
Jan 01, 2009
Volume
1
Pages
53–59
Identifiers
PMID: 21935307
Source
Medline
Keywords
License
Unknown

Abstract

Within the Italian health care system, intermittent etanercept is a cost-effective therapeutic option compared with nonsystemic therapy for the group of patients with moderate and severe plaque psoriasis. For patients with PASI ≥ 20, cost-effectiveness of etanercept is even greater.

Report this publication

Statistics

Seen <100 times